Assistant Professor of Pediatrics, Dana-Farber Cancer Institute
Pediatric Hematology & Oncology
Dr. Kimberly Stegmaier, MD
|
|
Give Review
Kimberly Stegmaier is an expert in the field of Pediatric Hematology & Oncology. She studied medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. She over the years received 2 awards: "Elected Member" and "Super Doctor". Kimberly Stegmaier has written publications. She has 39 publications published with PubMed. The lastest paper is: 'The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms.'
Publications
- The genomic landscape of juvenile myelomonocytic leukemia.
- Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia.
- The genomic landscape of pediatric ewing sarcoma.
- Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.
- An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
- SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia.
- A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.
- MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
- In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling.
- Mutational heterogeneity in cancer and the search for new cancer-associated genes.
- Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation.
- SYK regulates mTOR signaling in AML.
- Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer.
- Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children''s Oncology Group.
- High-throughput gene expression profiling of memory differentiation in primary human T cells.
- Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
- Literature Lab: a method of automated literature interrogation to infer biology from microarray analysis.
- Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
- Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.
- A method for high-throughput gene expression signature analysis.
- Genomic approaches in acute leukemia.
- Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with ...
- Gefitinib induces myeloid differentiation of acute myeloid leukemia.
- Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.
- Targeting NOTCH1 in hematopoietic malignancy.
- Chemical genomics and combo therapy.
- Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
- Proteomic and genetic approaches identify Syk as an AML target.
- Identification of AML1-ETO modulators by chemical genomics.
- The intersection of genetic and chemical genomic screens identifies GSK-3? as a target in human acute myeloid leukemia.
- Genetic and proteomic approaches to identify cancer drug targets.
- Genomic approaches to small molecule discovery.
- The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms.
- TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia.
- The TEL gene and human leukemia.
- Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia.
- Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms.
- Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood.
Schools
Harvard Medical School
Children39s Hospital Boston
Dana Farber Cancer Instit and Chldrn39s Hospital
Conditions Treated
- Anemia
- Hodgkin's Disease
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Awards
- Elected Member
- Super Doctor
Education
-
Boston Children's Hospital -
Harvard Medical School
Hospital
-
Boston Children's Hospital -
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Holcombe E. Grier, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Loren D. Walensky, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Amy L. Billett, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Alan D. Dandrea, MD
This Doctor is OpenDoctor Recommended.
|